%3Aformat(webp)&w=3840&q=75)
aXichem: Sales growth in the forecast
Research update Q2 2025
|2025-09-05
- Higher revenues than expected in Q2
- First commercial order for aXiphen in Brazil
- We raise our fair value estimate to SEK 4.26 (2.95) per share.
Investor interest in aXichem shares continues, and the share price has risen by 190 per cent since the start of the year. The company reported sales of SEK 6.8 million in Q2, which was higher than our forecast of SEK 6.2 million. At the same time, costs were significantly higher than our estimates. In total, the company reported an operating profit of SEK -3.4 million, compared with our expectation of SEK -3.2 million. We have reviewed the probability in our model, which has affected the fair value. The company still has some way to go before achieving profitability in aXivite, but the positive development in both the US and Europe justifies an increase.
Read our research update. The research update is available in Swedish
%3Aformat(webp)&w=3840&q=75)
Tobias Karlsson
Analyst
%3Aformat(webp)&w=3840&q=75)
Martin Dominique
Chief Analyst